- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06872216
Effect of Cupping Therapy on Microcirculation in Healthy Volunteers (CTWN)
March 6, 2025 updated by: Tuğba Karaman, Tokat Gaziosmanpasa University
Evaluation the Impact of Dry Cupping Therapy on Microvascular Reactivity by Near-infrared Spectroscopy with Vascular Occlusion Test in Healthy Volunteers
Twenty healthy volunteers were included in the study.
The NIRS was placed on the thenar region of the hand.
The vascular occlusion protocol had been done before and after cupping therapy (CT).
Regional oxygen saturation (rSO2), the times to the lowest and highest values were recorded.
The occlusion slope, the recovery slope and the first 10 second recovery slope were calculated.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Participants rested in a seated position at standard temperature for at least 10 minutes.
A blood pressure cuff was applied to the upper arm, and the NIRS device (Covidien INVOS™ 5100C Cerebral/Somatic Oximeter, Dublin) was used to monitor regional oxygen levels in the thenar region of the hand throughout the protocol.
After a 3-minute stabilization period, the vascular occlusion protocol commenced: the blood pressure cuff was inflated rapidly within 3-4 seconds to 50 mmHg above the baseline systolic blood pressure and maintained for 3 minutes, then deflated within 1 second.
The participant rested for another 10 minutes before a certified cupping therapist placed a plastic therapy cup on the forearm, 5 cm from the medial and lateral epicondyles.
The size of the cup was based on the participant's forearm, covering 50% of the area.
The cup was vacuumed twice using a manual hand pump and left in place for 5 minutes before the air was released through the valve.
Following a 3-minute stabilization period, the vascular occlusion protocol was repeated.
During the test, rSO2 values and the time to reach the lowest and highest values were recorded.
Using this data, the occlusion slope, recovery slope, and 10-second recovery slope were calculated.
The occlusion slope was determined by the formula [(baseline rSO2 - minimum rSO2) / time to lowest rSO2], in %/minute.
The recovery slope was calculated as [(minimum rSO2 - maximum rSO2) / time to reach the highest rSO2], in %/second.
The 10-second recovery slope was calculated as [(minimum rSO2 - rSO2 at 10 seconds) / 10 seconds].
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokat, Turkey, 60100
- Tokat Gaziosmanpasa University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18-65 years old
- Healthy
Exclusion Criteria:
- Smoking or using tobacco products
- Taking alcohol or other substances, or any medication
- Have conditions affecting microcirculation
- Have acute or chronic pain
- Anemia
- Obesity
- Reynaud's phenomenon
- Baseline blood pressure being 140-90mmHg or above
- sPO2 value being below 96%
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: cupping therapy
nırs monitored during vot test pre-post cupping therapy
|
After the initial vascular occlusion test and a subsequent 10-minute rest period, the plastic therapy cup was placed on the forearm, 5 cm away from the medial and lateral epicondyles by a certified cupping therapist.
The size of used cup was determined according to the size of the volunteer's forearm which cover 50% of the area.
The cup was vacuumed two times full pumping with a manual hand pump and remained in place for 5 minutes.
And then the air was removed by releasing the cups through the release valve.
A blood pressure cuff was placed on the upper arm.
The adult probe of the NIRS device (Covidien INVOS™ 5100C Cerebral/Somatic Oximeter, Dublin) was placed on the thenar region of the ipsilateral hand and the regional oxygen value was recorded during all study term.
Baseline arterial pressure and oxygen saturation were monitored (GE Healthcare Oy, Helsinki, Finland) from the side of dominant hand and recorded.
After a 3-minute stabilization period, the vascular occlusion protocol was started.
The blood pressure cuff was rapidly inflated within 3-4 seconds to 50 mmHg above baseline systolic blood pressure and kept at this pressure during 3 minutes.
Following this, the cuff was deflated within 1 second.
Five minutes after cupping therapy this protocol had done again.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the rSO2 values
Time Frame: Periprocedural
|
monitored at tenar region on the dominant hand with near infrared spectrometry
|
Periprocedural
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the time to reach the lowest rSO2
Time Frame: Periprocedural
|
the interval of the basal and minimal rSO2 is measured
|
Periprocedural
|
|
the time to reach the highest values
Time Frame: Periprocedural
|
the interval of the minimal to maximal rSO2 is measured
|
Periprocedural
|
|
the occlusion slope
Time Frame: Periprocedural
|
The occlusion slope was calculated based on time to reach to the lowest rSO2 as [(baseline rSO2 -minimum rSO2)/ time to lowest rSO2], %/minute.
|
Periprocedural
|
|
Recovery slope
Time Frame: Periprocedural
|
Recovery slope was calculated based on the time to reach the highest rSO2 value as [(minimum rSO2 - maximum rSO2)/ time to reach the highest rSO2], %/second.
|
Periprocedural
|
|
The 10th second recovery slope
Time Frame: Periprocedural
|
The 10th second recovery slope was calculated as [(minimum rSO2 - at first 10th second rSO2)/ 10 second].
|
Periprocedural
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Gomez H, Torres A, Polanco P, Kim HK, Zenker S, Puyana JC, Pinsky MR. Use of non-invasive NIRS during a vascular occlusion test to assess dynamic tissue O(2) saturation response. Intensive Care Med. 2008 Sep;34(9):1600-7. doi: 10.1007/s00134-008-1145-1. Epub 2008 Jun 4.
- Liu W, Piao S, Meng Xi, Wei L. Effects of cupping on blood flow under skin of back in healthy human. World Journal of Acupuncture - Moxibustion. 2013; 23 (3): 50-52. doi.org/10.1016/S1003-5257(13)60061-6.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2022
Primary Completion (Actual)
January 1, 2023
Study Completion (Actual)
May 1, 2023
Study Registration Dates
First Submitted
February 18, 2025
First Submitted That Met QC Criteria
March 6, 2025
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
March 6, 2025
Last Verified
February 1, 2025
More Information
Terms related to this study
Other Study ID Numbers
- NIRS-CUPPİNG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.